1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014

Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014" provides data on the Refractory Acute Myeloid Leukemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Acute Myeloid Leukemia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Acute Myeloid Leukemia. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Refractory Acute Myeloid Leukemia Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Refractory Acute Myeloid Leukemia 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Refractory Acute Myeloid Leukemia 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Refractory Acute Myeloid Leukemia 32
Mar 12, 2014: Cornerstone Pharmaceuticals Lead Compound CPI-613 Demonstrates Ability to Disrupt Growth of Cancer Cells 32
Jun 25, 2013: FDA Issues Partial Clinical Hold On Cell Therapeutics's Tosedostat For Treatment Of Blood Cancer 32
Jun 13, 2013: Sunesis Pharma Announces Data And Safety Monitoring Board Recommends Continuation Of VALOR Trial With No Change To Study Conduct 33
Apr 01, 2013: Clavis Pharma Reports Negative Outcome Of Phase III CLAVELA Trial With Elacytarabine In Patients With Acute Myeloid Leukemia 33
Clinical Trial Profiles 35
Clinical Trial Overview of Top Companies 35
Novartis AG 35
Clinical Trial Overview of Novartis AG 35
Pfizer Inc. 37
Clinical Trial Overview of Pfizer Inc. 37
Celgene Corporation 38
Clinical Trial Overview of Celgene Corporation 38
Sanofi 39
Clinical Trial Overview of Sanofi 39
C. H. Boehringer Sohn AG and Co. KG 40
Clinical Trial Overview of C. H. Boehringer Sohn AG and Co. KG 40
Ambit Biosciences Corporation 41
Clinical Trial Overview of Ambit Biosciences Corporation 41
F. Hoffmann-La Roche Ltd. 42
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 42
AROG Pharmaceuticals LLC 43
Clinical Trial Overview of AROG Pharmaceuticals LLC 43
Amgen Inc. 44
Clinical Trial Overview of Amgen Inc. 44
AbbVie Inc. 45
Clinical Trial Overview of AbbVie Inc. 45
Clinical Trial Overview of Top Institutes / Government 46
National Cancer Institute 46
Clinical Trial Overview of National Cancer Institute 46
Fred Hutchinson Cancer Research Center 49
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 49
Children's Oncology Group 50
Clinical Trial Overview of Children's Oncology Group 50
The University of Texas M. D. Anderson Cancer Center 51
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 51
Stanford University 52
Clinical Trial Overview of Stanford University 52
Washington University School of Medicine 53
Clinical Trial Overview of Washington University School of Medicine 53
Roswell Park Cancer Institute 54
Clinical Trial Overview of Roswell Park Cancer Institute 54
Sidney Kimmel Comprehensive Cancer Center 55
Clinical Trial Overview of Sidney Kimmel Comprehensive Cancer Center 55
Case Comprehensive Cancer Center 56
Clinical Trial Overview of Case Comprehensive Cancer Center 56
Five Key Clinical Profiles 57
Appendix 117
Abbreviations 117
Definitions 117
Research Methodology 118
Secondary Research 118
About GlobalData 119
Contact Us 119
Disclaimer 119
Source 120

List of Tables
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region, 2014* 7
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014* 10
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries, 2014* 11
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries, 2014* 12
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 13
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 14
Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase, 2014* 21
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 22
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Refractory Acute Myeloid Leukemia Therapeutics, Global, Withdrawn Clinical Trials, 2014* 25
Refractory Acute Myeloid Leukemia Therapeutics, Global, Terminated Clinical Trials, 2014* 26
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Refractory Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 28
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 35
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014* 37
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014* 38
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sanofi, 2014* 39
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by C. H. Boehringer Sohn AG and Co. KG, 2014* 40
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Ambit Biosciences Corporation, 2014* 41
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014* 42
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AROG Pharmaceuticals LLC, 2014* 43
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014* 44
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc., 2014* 45
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 46
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014* 49
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2014* 50
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by The University of Texas M. D. Anderson Cancer Center, 2014* 51
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 52
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014* 53
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Roswell Park Cancer Institute, 2014* 54
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Sidney Kimmel Comprehensive Cancer Center, 2014* 55
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials Market, Global, Clinical Trials by Case Comprehensive Cancer Center, 2014* 56

List of Figures
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Region (%), 2014* 7
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 8
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 9
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014* 10
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014* 11
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 12
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014* 13
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014* 14
Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, G7 Countries (%), 2014* 15
Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 16
Refractory Acute Myeloid Leukemia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 17
Proportion of Refractory Acute Myeloid Leukemia to Oncology Clinical Trials, E7 Countries (%), 2014* 18
Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Phase, 2014* 19
Refractory Acute Myeloid Leukemia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014* 20
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Phase (%), 2014* 21
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 22
Refractory Acute Myeloid Leukemia Therapeutics, Global, Clinical Trials by Trial Status, 2014* 23
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, by End Point Status, 2014* 24
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 27
Refractory Acute Myeloid Leukemia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 28
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 29
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 30
Refractory Acute Myeloid Leukemia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 31
GlobalData Methodology 118

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market  Forecast-2023

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic lymphocytic leukemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.